NDC 70518-1357-2 - Citalopram Hydrobromide
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70518-1357
- Requested NDC
- 70518-1357-2
- Package NDCs from labels
- 70518-1357-0, 70518-1357-2, 70518-1357-1
- Manufacturer
- REMEDYREPACK INC.
- Effective date
- 2025-02-10
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Citalopram Hydrobromide - REMEDYREPACK INC. | REMEDYREPACK INC. | 2025-02-10 | HUMAN PRESCRIPTION DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Citalopram | CITALOPRAM | Cipla USA Inc. | 0580559a-783a-4a0a-8d81-ee30a29077c5 | 2024-08-01 | Boxed warning, Warnings, Adverse reactions | 283672 200371 309314 I1E9D14F36 |
| CITALOPRAM HYDROBROMIDE | CITALOPRAM | Exelan Pharmaceuticals Inc. | a8e8fde2-8392-4d5b-902b-e2b9dd55a02d | 2024-08-01 | Boxed warning, Warnings, Adverse reactions | 283672 200371 309314 I1E9D14F36 |
| Citalopram Hydrobromide | CITALOPRAM HYDROBROMIDE | NuCare Pharmaceuticals, Inc. | 4f45c818-b324-6ca6-e054-00144ff8d46c | 2024-07-17 | Boxed warning, Warnings, Adverse reactions | ANDA078216 200371 I1E9D14F36 |
| Citalopram Hydrobromide | CITALOPRAM HYDROBROMIDE | NuCare Pharmaceuticals,Inc. | 579836d8-64ed-de2d-e053-2a91aa0a8392 | 2024-07-11 | Boxed warning, Warnings, Adverse reactions | ANDA078216 200371 I1E9D14F36 |
| Citalopram Hydrobromide | CITALOPRAM HYDROBROMIDE | NuCare Pharmaceuticals,Inc. | 549a5b3f-4928-1ae5-e054-00144ff8d46c | 2024-07-10 | Boxed warning, Warnings, Adverse reactions | ANDA078216 309314 I1E9D14F36 |
| Citalopram | CITALOPRAM HYDROBROMIDE | QUALLENT PHARMACEUTICALS HEALTH LLC | e0822069-9672-4d4c-bc1a-8739b0dd045c | 2024-07-01 | Boxed warning, Warnings, Adverse reactions | 283672 200371 309314 I1E9D14F36 |
| Citalopram | CITALOPRAM | Mylan Pharmaceuticals Inc. | 825c0c49-5fbf-6d8b-cb8c-94ebf0eda043 | 2024-06-23 | Boxed warning, Warnings, Adverse reactions | 283672 200371 309314 I1E9D14F36 |
| Citalopram Hydrobromide | CITALOPRAM HYDROBROMIDE | NuCare Pharmaceuticals,Inc. | 9987a273-e6d7-54cd-e053-2a95a90a0aaa | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | ANDA078216 200371 I1E9D14F36 |
| Citalopram | CITALOPRAM HYDROBROMIDE | Aurobindo Pharma Limited | 2632b547-2e13-447f-ac85-c774e437d6a8 | 2024-05-17 | Boxed warning, Warnings, Adverse reactions | 283672 200371 309314 I1E9D14F36 |
| Citalopram Hydrobromide | CITALOPRAM HYDROBROMIDE | Aurobindo Pharma Limited | e7a2cbdd-1bdb-4e59-a3dd-298a189753ae | 2024-05-08 | Boxed warning, Warnings, Adverse reactions | I1E9D14F36 |
| Citalopram | CITALOPRAM | A-S Medication Solutions | c91684c7-fddb-4cf0-9711-b0484c8c7e8b | 2024-04-29 | Boxed warning, Warnings, Adverse reactions | 200371 I1E9D14F36 |
| Citalopram | CITALOPRAM | A-S Medication Solutions | 17af7a8d-ef57-4253-96ed-e457e0062eb5 | 2024-04-29 | Boxed warning, Warnings, Adverse reactions | 309314 I1E9D14F36 |
| Citalopram | CITALOPRAM | A-S Medication Solutions | 04ac5286-fc2e-4990-a574-ea21131ef731 | 2024-04-29 | Boxed warning, Warnings, Adverse reactions | 283672 I1E9D14F36 |
| Citalopram | CITALOPRAM HYDROBROMIDE | A-S Medication Solutions | fc766b76-18c1-42cd-b276-f720f5821c11 | 2024-04-25 | Boxed warning, Warnings, Adverse reactions | 200371 I1E9D14F36 |
| Citalopram Hydrobromide | CITALOPRAM HYDROBROMIDE | Camber Pharmaceuticals, Inc. | dc7b3f88-ee55-4e3e-9ed4-fc06aa7620cc | 2024-02-29 | Boxed warning, Warnings, Adverse reactions | I1E9D14F36 |
| Citalopram | CITALOPRAM HYDROBROMIDE | A-S Medication Solutions | c6730edc-7226-4521-a04a-1bf296b01b8d | 2024-02-13 | Boxed warning, Warnings, Adverse reactions | 309314 I1E9D14F36 |
| Citalopram | CITALOPRAM | NuCare Pharmaceuticals,Inc. | 0dfb11d9-f48d-56ee-e063-6294a90ad256 | 2024-01-02 | Boxed warning, Warnings, Adverse reactions | 309314 I1E9D14F36 |
| Citalopram Hydrobromide | CITALOPRAM HYDROBROMIDE | A-S Medication Solutions | 9059c8f1-8755-492d-aba2-5f5088ce69d3 | 2023-12-26 | Boxed warning, Warnings, Adverse reactions | ANDA078216 309314 I1E9D14F36 |
| Citalopram Hydrobromide | CITALOPRAM HYDROBROMIDE | A-S Medication Solutions | 9d2f8f9f-9710-48e0-bc18-105a2af1073b | 2023-12-04 | Boxed warning, Warnings, Adverse reactions | ANDA078216 200371 I1E9D14F36 |
| Celexa | CITALOPRAM | Allergan, Inc. | 4259d9b1-de34-43a4-85a8-41dd214e9177 | 2023-10-09 | Boxed warning, Warnings, Adverse reactions | 283672 200371 309314 I1E9D14F36 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.